title: Colon cancer, version 3.2014.
abstract: The NCCN Guidelines for Colon Cancer address diagnosis, pathologic staging, surgical management, perioperative treatment, posttreatment surveillance, management of recurrent and metastatic disease,and survivorship. This portion of the guidelines focuses on the use of systemic therapy in metastatic disease. The management of metastatic colorectal cancer involves a continuum of care in which patients are exposed sequentially to a variety of active agents, either in combinations or as single agents. Choice of therapy is based on the goals of treatment, the type and timing of prior therapy, the different efficacy and toxicity profiles of the drugs, the mutational status of the tumor, and patient preference.
authors.forename: Al B
authors.initials: AB
authors.lastname: Benson
authors.forename: Alan P
authors.initials: AP
authors.lastname: Venook
authors.forename: Tanios
authors.initials: T
authors.lastname: Bekaii-Saab
authors.forename: Emily
authors.initials: E
authors.lastname: Chan
authors.forename: Yi-Jen
authors.initials: YJ
authors.lastname: Chen
authors.forename: Harry S
authors.initials: HS
authors.lastname: Cooper
authors.forename: Paul F
authors.initials: PF
authors.lastname: Engstrom
authors.forename: Peter C
authors.initials: PC
authors.lastname: Enzinger
authors.forename: Moon J
authors.initials: MJ
authors.lastname: Fenton
authors.forename: Charles S
authors.initials: CS
authors.lastname: Fuchs
authors.forename: Jean L
authors.initials: JL
authors.lastname: Grem
authors.forename: Steven
authors.initials: S
authors.lastname: Hunt
authors.forename: Ahmed
authors.initials: A
authors.lastname: Kamel
authors.forename: Lucille A
authors.initials: LA
authors.lastname: Leong
authors.forename: Edward
authors.initials: E
authors.lastname: Lin
authors.forename: Wells
authors.initials: W
authors.lastname: Messersmith
authors.forename: Mary F
authors.initials: MF
authors.lastname: Mulcahy
authors.forename: James D
authors.initials: JD
authors.lastname: Murphy
authors.forename: Steven
authors.initials: S
authors.lastname: Nurkin
authors.forename: Eric
authors.initials: E
authors.lastname: Rohren
authors.forename: David P
authors.initials: DP
authors.lastname: Ryan
authors.forename: Leonard
authors.initials: L
authors.lastname: Saltz
authors.forename: Sunil
authors.initials: S
authors.lastname: Sharma
authors.forename: David
authors.initials: D
authors.lastname: Shibata
authors.forename: John M
authors.initials: JM
authors.lastname: Skibber
authors.forename: Constantinos T
authors.initials: CT
authors.lastname: Sofocleous
authors.forename: Elena M
authors.initials: EM
authors.lastname: Stoffel
authors.forename: Eden
authors.initials: E
authors.lastname: Stotsky-Himelfarb
authors.forename: Christopher G
authors.initials: CG
authors.lastname: Willett
authors.forename: Kristina M
authors.initials: KM
authors.lastname: Gregory
authors.forename: Deborah A
authors.initials: DA
authors.lastname: Freedman-Cass
mesh_terms: D020533:Angiogenesis Inhibitors / Q000009:adverse effects / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized / Q000009:adverse effects / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use; D000068258:Bevacizumab; D002166:Camptothecin / Q000009:adverse effects / Q000031:analogs & derivatives / Q000627:therapeutic use; D000069287:Capecitabine; D000068818:Cetuximab; D003110:Colonic Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery*; D003841:Deoxycytidine / Q000009:adverse effects / Q000031:analogs & derivatives / Q000627:therapeutic use; D018450:Disease Progression; D005472:Fluorouracil / Q000009:adverse effects / Q000031:analogs & derivatives / Q000627:therapeutic use; D020558:GTP Phosphohydrolases / Q000235:genetics; D006801:Humans; D002955:Leucovorin / Q000009:adverse effects / Q000627:therapeutic use; D008113:Liver Neoplasms / Q000188:drug therapy / Q000556:secondary* / Q000601:surgery; D008565:Membrane Proteins / Q000235:genetics; D009944:Organoplatinum Compounds / Q000009:adverse effects / Q000627:therapeutic use; D010071:Oxaloacetates; D011518:Proto-Oncogene Proteins / Q000235:genetics; D048493:Proto-Oncogene Proteins B-raf / Q000235:genetics; D016283:Proto-Oncogene Proteins p21(ras); D016896:Treatment Outcome; D018631:ras Proteins / Q000235:genetics
chemical_list: D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; C117307:KRAS protein, human; D008565:Membrane Proteins; D009944:Organoplatinum Compounds; D010071:Oxaloacetates; D011518:Proto-Oncogene Proteins; D003841:Deoxycytidine; D000068258:Bevacizumab; D000069287:Capecitabine; C482119:BRAF protein, human; D048493:Proto-Oncogene Proteins B-raf; D020558:GTP Phosphohydrolases; C579846:NRAS protein, human; D016283:Proto-Oncogene Proteins p21(ras); D018631:ras Proteins; D000068818:Cetuximab; D002955:Leucovorin; D005472:Fluorouracil; D002166:Camptothecin